Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | GABBR2 | O75899 | 4/20 | 0.48 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3113899 | 0.90 | ADORA1 (0.45) | ADORA1RAB9ANPC1ADORA3ADORA2A | |
| SCHEMBL3116326 | 0.85 | GABBR2 (0.44) | ADORA1RAB9ANPC1ADORA3ADORA2A | |
| SCHEMBL3111729 | 0.85 | ADORA3 (0.54) | ADORA1ADORA3ADORA2AGABBR2GABBR1 | |
| SCHEMBL3126761 | 0.82 | ADORA3 (0.55) | ADORA1RAB9ANPC1ADORA3ADORA2A | |
| SCHEMBL3121999 | 0.81 | PDE4A (0.45) | RAB9ANPC1GABBR2GABBR1TP53 | |
| SCHEMBL3123037 | 0.79 | PDE5A (0.48) | ADORA1RAB9AADORA3ADORA2ATP53 | |
| SCHEMBL3116087 | 0.79 | GABBR2 (0.74) | ADORA1RAB9ANPC1ADORA3ADORA2A | |
| SCHEMBL27735630 | 0.79 | GABBR2 (0.40) | ADORA1ADORA3ADORA2AGABBR2GABBR1 | |
| SCHEMBL3108180 | 0.77 | GABBR2 (0.41) | ADORA1ADORA3ADORA2AGABBR2GABBR1 | |
| SCHEMBL3118478 | 0.77 | ADORA3 (0.49) | ADORA1RAB9ANPC1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| EP-1896428-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS | Novartis AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006136442-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OP GABA B MEDIATED NERVOUS SYSTEM DISORDERS | NOVARTIS AG (CH) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | DPYD, NUDT1, HPRT1 | ADORA1 17/4885RAB9A 3389/4885NPC1 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.